Get the Stockscreener App
71.01
0.18%
-0.13
After Hours:
71.01
Globus Medical Inc stock is traded at $71.01, with a volume of 574.33K.
It is down -0.18% in the last 24 hours and down -1.57% over the past month.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
See More
Previous Close:
$71.14
Open:
$71.5
24h Volume:
574.33K
Relative Volume:
0.45
Market Cap:
$10.04B
Revenue:
$2.48B
Net Income/Loss:
$91.51M
P/E Ratio:
105.99
EPS:
0.67
Net Cash Flow:
$293.77M
1W Performance:
+0.04%
1M Performance:
-1.57%
6M Performance:
-3.94%
1Y Performance:
+38.69%
1-Day Range:
$70.74
$71.80
1-Week Range:
$69.65
$74.34
52-Week Range:
$49.33
$94.93
Globus Medical Inc Stock (GMED) Company Profile
Name
Globus Medical Inc
Sector
Industry
Phone
610-930-1800
Address
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
71.01 | 10.04B | 2.48B | 91.51M | 293.77M | 0.67 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-20-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-18-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-19-23 | Upgrade | Stifel | Hold → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-13-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-10-23 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-10-23 | Downgrade | Loop Capital | Buy → Hold |
| Feb-10-23 | Downgrade | Needham | Buy → Hold |
| Feb-10-23 | Downgrade | Truist | Buy → Hold |
| Feb-10-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-28-22 | Initiated | Wells Fargo | Overweight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-13-21 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-29-21 | Initiated | Loop Capital | Buy |
| Feb-18-21 | Resumed | Needham | Buy |
| Dec-08-20 | Initiated | Citigroup | Buy |
| Oct-20-20 | Initiated | Stifel | Hold |
| Aug-06-20 | Reiterated | Needham | Buy |
| Aug-06-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-21-20 | Initiated | Northland Capital | Market Perform |
| Jul-06-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-08-20 | Reiterated | Needham | Buy |
| Mar-18-20 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Aug-02-19 | Reiterated | Needham | Buy |
| May-24-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| May-03-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Upgrade | UBS | Neutral → Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-27-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-18 | Reiterated | Needham | Buy |
| Apr-04-18 | Upgrade | Needham | Hold → Buy |
View All
Globus Medical Inc Stock (GMED) Latest News
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Spine Surgery Robots Market Size, Share, Trends, Competitive - openPR.com
Globus Medical Schedules First Quarter Earnings Release and Conference Call - GlobeNewswire
Globus Medical Schedules First Quarter Earnings Release and Conference Call | GMED Stock News - GuruFocus
Globus Medical, Inc. Scheduled to Release Q1 2025 Financial Results on May 8, 2025 - Nasdaq
Globus Medical Announces Q1 Earnings Date: Leading Musculoskeletal Tech Firm Reports May 8 - Stock Titan
Here's How Much You Would Have Made Owning Globus Medical Stock In The Last 10 Years - Benzinga
Interspinous Spacers Market Deep Research Report with Forecast to 2032 | Alphatec Spine, Inc., Globus Medical - openPR.com
Is The Market Rewarding Globus Medical, Inc. (NYSE:GMED) With A Negative Sentiment As A Result Of Its Mixed Fundamentals? - Yahoo Finance
BTIG Revises Price Target for Globus Medical (GMED) Amid MedTech - GuruFocus
International Growth Drives GMED Stock Amid Fierce Competition - MSN
Spinal Column Market Deep Research Report with Forecast by 2032 | - openPR.com
Orthobiologics Market Set to Witness Significant Growth - openPR.com
Truist Adjusts Price Target for Globus Medical (GMED) to $80 | G - GuruFocus
Breaking Down Globus Medical: 5 Analysts Share Their Views - Benzinga
Truist Trims Price Target on Globus Medical to $80 From $82, Keeps Hold Rating - marketscreener.com
GMED Stock May Benefit Following the Acquisition of Nevro - MSN
JMP maintains Market Perform on Globus Medical stock By Investing.com - Investing.com Canada
Intramedullary Nail Market size to worth USD 1,537 Million by 2032, says Coherent Market Insights - GlobeNewswire Inc.
Degenerative Disc Disease Treatment Market Set to Witness - openPR.com
This Globus Medical Insider Reduced Their Stake By 100% - simplywall.st
Globus acquires US medical device company Nevro - Yahoo Finance
Globus Medical Completes Acquisition of Nevro Corp. - MyChesCo
Nevro Corp completes merger with Globus Medical - Investing.com Australia
Globus Medical Closes Acquisition of Nevro - MarketScreener
Globus Medical Acquires Nevro Corp. - citybiz
Nevro Corp completes merger with Globus Medical By Investing.com - Investing.com South Africa
Globus Medical completes acquisition of Nevro Corp. - GlobeNewswire
Major Medical Tech Merger: Globus Medical's $2.5B Market Push Through Nevro Acquisition - Stock Titan
Globus Medical, Inc. (NYSE:GMED) Shares Bought by Vanguard Group Inc. - MarketBeat
$100 Invested In Globus Medical 10 Years Ago Would Be Worth This Much Today - Benzinga
Robotic-assisted Surgery Systems Market Set to Witness - openPR.com
Total Disc Replacement Market Future Business Opportunities - openPR.com
Levi & Korsinsky Reminds Shareholders of an Investigation into Globus Medical, Inc. (GMED) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Despite the downward trend in earnings at Globus Medical (NYSE:GMED) the stock grows 7.0%, bringing five-year gains to 80% - Yahoo Finance
Orthobiologics Market Future Business Opportunities - openPR
New Product Launches Benefit GMED Stock Amid Macro Issues - MSN
1 Healthcare Stock with Solid Fundamentals and 2 to Turn Down - Yahoo Finance
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally? - Yahoo Finance
Globus Medical (NYSE:GMED) shareholders notch a 11% CAGR over 5 years, yet earnings have been shrinking - simplywall.st
Spinal Fusion Device Market Forecast Report and Company Analysis 2025-2033 Featuring Medtronic, Stryker, Zimmer Biomet, Orthofix Medical, NuVasive, Globus Medical, Xtant Medical, and Alphatec – Ortho Spine News - OrthoSpineNews
How Is The Market Feeling About Globus Medical? - Benzinga
Should You Hold Globus Medical Stock in Your Portfolio Now? - MSN
Spinal Fusion Device Market Forecast Report and Company - GlobeNewswire
Truist Financial Has Lowered Expectations for Globus Medical (NYSE:GMED) Stock Price - MarketBeat
Globus Medical Inc Stock (GMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):